Actively Recruiting
Evaluation of Safety of Acellular Dermal Matrix(ADM) in Breast Reconstruction
Led by DOF Inc. · Updated on 2026-04-28
120
Participants Needed
1
Research Sites
141 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to evaluate the safety of Acellular Dermal Matrix(ADM) processed by CO2 supercritical fluid technology against other acellular dermal matrix products from different companies that have been washed with detergents in patients undergoing breast reconstruction surgery with implants due to the breast cancer.
CONDITIONS
Official Title
Evaluation of Safety of Acellular Dermal Matrix(ADM) in Breast Reconstruction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female patients aged 19 to 79 years
- Undergoing implant-based breast reconstruction using SC DERM�ae Recon following mastectomy due to breast cancer
- Provide written informed consent and willing to comply with study procedures
- Patients who underwent implant-based breast reconstruction with acellular dermal matrix between March 1, 2021, and March 31, 2024 (retrospective control group)
You will not qualify if you...
- Patients deemed inappropriate by investigators (e.g., unable to undergo required assessments)
- Patients with no recorded follow-up visits after acellular dermal matrix application (retrospective control group)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Seoul National University Hospital
Seoul, Seoul, South Korea, 03080
Actively Recruiting
Research Team
K
kiyong Hong, Ph.D
CONTACT
H
Hyejin Ryu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here